- Home
- CLNN vs CALC Comparison
CLNN vs CALC Comparison
Compare CLNN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- CALC
- Stock Information
- Founded
- CLNN 2012
- CALC 2011
- Country
- CLNN United States
- CALC United States
- Employees
- CLNN N/A
- CALC N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- CALC Health Care
- Exchange
- CLNN Nasdaq
- CALC Nasdaq
- Market Cap
- CLNN 26.1M
- CALC 20.9M
- IPO Year
- CLNN N/A
- CALC N/A
- Fundamental
- Price
- CLNN $2.66
- CALC $1.91
- Analyst Decision
- CLNN Strong Buy
- CALC Strong Buy
- Analyst Count
- CLNN 5
- CALC 3
- Target Price
- CLNN $40.00
- CALC $16.33
- AVG Volume (30 Days)
- CLNN 74.4K
- CALC 33.2K
- Earning Date
- CLNN 05-07-2025
- CALC 05-14-2025
- Dividend Yield
- CLNN N/A
- CALC N/A
- EPS Growth
- CLNN N/A
- CALC N/A
- EPS
- CLNN N/A
- CALC N/A
- Revenue
- CLNN $350,000.00
- CALC N/A
- Revenue This Year
- CLNN N/A
- CALC N/A
- Revenue Next Year
- CLNN $2,066.67
- CALC N/A
- P/E Ratio
- CLNN N/A
- CALC N/A
- Revenue Growth
- CLNN N/A
- CALC N/A
- 52 Week Low
- CLNN $2.55
- CALC $1.43
- 52 Week High
- CLNN $9.20
- CALC $6.02
- Technical
- Relative Strength Index (RSI)
- CLNN 37.77
- CALC 56.52
- Support Level
- CLNN $2.91
- CALC $1.86
- Resistance Level
- CLNN $2.90
- CALC $2.04
- Average True Range (ATR)
- CLNN 0.19
- CALC 0.14
- MACD
- CLNN 0.00
- CALC 0.05
- Stochastic Oscillator
- CLNN 18.33
- CALC 64.79
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.